Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus SEMPREX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus SEMPREX D.
CHILDREN'S ALLEGRA ALLERGY vs SEMPREX-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
Fexofenadine 60 mg orally twice daily or 180 mg once daily.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours) in healthy adults. In children aged 6–12 years, half-life is similar. Clinical context: allows once-daily dosing.
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Fexofenadine is excreted primarily unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for a minor portion.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination